Review Article

An Update on Mesenchymal Stem Cell-Centered Therapies in Temporomandibular Joint Osteoarthritis

Yifan Zhao and Liang Xie

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China

Correspondence should be addressed to Liang Xie; lxie@scu.edu.cn

Received 14 November 2020; Revised 20 February 2021; Accepted 19 March 2021; Published 2 April 2021

Academic Editor: Yohei Hayashi

Copyright © 2021 Yifan Zhao and Liang Xie. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Temporomandibular joint osteoarthritis (TMJOA) is a degenerative disease characterized by cartilage degeneration, disrupted subchondral bone remodeling, and synovitis, seriously affecting the quality of life of patients with chronic pain and functional disabilities. Current treatments for TMJOA are mainly symptomatic therapies without reliable long-term efficacy, due to the limited self-renewal capability of the condyle and the poorly elucidated pathogenesis of TMJOA. Recently, there has been increased interest in cellular therapies for osteoarthritis and TMJ regeneration. Mesenchymal stem cells (MSCs), self-renewing and multipotent progenitor cells, play a promising role in TMJOA treatment. Derived from a variety of tissues, MSCs exert therapeutic effects through diverse mechanisms, including chondrogenic differentiation; fibrocartilage regeneration; and trophic, immunomodulatory, and anti-inflammatory effects. Here, we provide an overview of the therapeutic roles of various tissue-specific MSCs in osteoarthritic TMJ or TMJ regenerative tissue engineering, with an additional focus on joint-resident stem cells and other cellular therapies, such as exosomes and adipose-derived stromal vascular fraction (SVF). Additionally, we summarized the updated pathogenesis of TMJOA to provide a better understanding of the pathological mechanisms of cellular therapies. Although limitations exist, MSC-centered therapies still provide novel, innovative approaches for TMJOA treatment.

1. Introduction

The temporomandibular joint (TMJ) is a synovial articulation that connects the mandibular condyle to the glenoid fossa of the temporal bone, and its inner space is divided into two compartments by a fibrocartilaginous TMJ disc [1]. It also has been considered as a bilateral diarthrodial joint according to its hinging and sliding movements and participation in essential life-support functions, such as chewing, swallowing, and speaking [2].

Osteoarthritis (OA) is a progressive degenerative condition that often causes deterioration of the cartilage and surrounding tissues, and TMJ is one of the most common sites affected by OA [3]. As a subtype of TMJ disorders (TMJDs), TMJOA is characterized by cartilage degeneration, disrupted subchondral bone remodeling, synovitis, and subsequent clinical symptoms, such as chronic orofacial pain, aberrant crepitations, restricted mandible motions, and functional disabilities [4, 5].

The diagnosis of TMJOA has mainly relied on evaluations of the aforementioned clinical features combined with radiographic assessments, and recent applications of cone-beam CT (CBCT) and MR imaging (MRI) further improved accuracy and sensitivity [6, 7]. Although the reported prevalence of TMJOA varies with the diverse diagnostic criteria, TMJOA still represents a growing health burden due to the limitations placed on patients’ quality of life and the substantial socioeconomic costs [8].

Currently, the management of TMJOA is contingent on the severity. Conservative therapies, including medications, occlusal splints, intra-articular injections, arthrocentesis, or arthroscopy, are preferred for patients in early or medium stages, while radical curative methods, such as open joint surgeries, are only performed in severe cases, associated with
high risks of complications [9–11]. However, due to the limited self-renewal capability of condylar structures, current treatments mainly focus on symptom alleviation and often fail to offer permanent recovery; thus, there is still a huge unmet clinical need for innovative approaches towards TMJOA [12].

As a large amount of literature has accumulated on the diverse functional roles played by stem cells, there is an emerging interest in the therapeutic effect of stem cells, mainly based on its immunoregulatory, anti-inflammatory, trophic activity, and multilineage differentiation potential [13–15]. Along with other cell-based therapies, increasing evidence has shed light on these regenerative medicines used in the field of TMJOA.

In this review, apart from a brief introduction about the unique construction and molecular composition of TMJ, we will discuss the latest research progress on the pathogenesis of TMJOA and summarize the diverse categories of stem cells and their pathological mechanism in TMJOA treatment, combined with other regenerative medicine, including exosomes, “minimally manipulated MSCs,” and platelet-rich plasma. Further, since MSC-centered cellular therapies are still in its infancy, we will also point out the limitations and controversies surrounding stem cell treatments, to provide an up-to-date review from a more objective perspective.

2. Pathogenesis of TMJOA

Due to the unique structure of the TMJ and its distinct composition of fibrocartilage, which predominantly contains type I collagen, the pathogenesis of TMJOA differs from the general OA that occurs in other joints, composed of hyaline cartilage to some extent [16]. The etiology of TMJOA is multifactorial [17], including risk factors from microtrauma, mechanical overload, malocclusion, bruxism, estrogen influence on systemic illness, and genetic variations [17–21]. Moreover, the pathogenesis of this disease is highly complicated and remains poorly understood, thus leading to current research focusing on underlying mechanisms (Figure 1). Therefore, we summarize several advances made in the last five years and add these to an outline from a previous review, especially regarding the aspects discussed below.

2.1. Inflammation. Although OA has long been considered a low-inflammatory and sterile disease [22], an increasing number of studies have suggested that inflammation is involved in the incidence and progression of TMJOA [23]. It was observed that a variety of inflammatory mediators and cytokines, such as tumor necrosis factor- (TNF-)α, interleukin- (IL-)17, IL-6, IL-1β, and IL-22, are more abundant in the synovial fluid of TMJOA-afflicted patients [24–26], accompanied by infiltration of immune cells, predominantly macrophages and T lymphocytes [23].

It has been well established that inflammatory cytokines, such as IL-1β, released from stimulated immune cells play a critical role in cartilage destruction by increasing cartilage degradation and suppressing the synthesis of cartilage matrix in TMJOA, and this tissue catabolism aggravates inflammation in a vicious cycle [17]. Recent studies suggest that sustained inflammation deteriorates the ultrastructure and nanomechanical properties of collagen fibrils in TMJ discs, partially through changes in the microenvironment of the extracellular matrix [27, 28]. In addition, osteoarthritis pain is also in close correlation with TMJ inflammation, which may be initiated by the production of inflammatory mediators, such as prostaglandins and leukotrienes [24]. For instance, TNF-α, the earliest and most representative cytokine in TMJOA, can directly stimulate nociceptors [29] and is related to sensory neuron hyperexcitability [30]. Recently, it was found that sexual distinctions in inflammatory stimuli of synoviocytes may contribute to the gender difference in TMJOA. While increased proinflammatory factors and enhanced synovitis were observed in female rats, the synoviocytes from female rats also possess higher sensitivity to inflammatory stimuli in an estrogen-related manner, with more recruited mononuclear cells and correspondingly elevated monocyte chemoattractant protein- (MCP-)1 levels [31].

2.2. Uncoupled Remodeling of Subchondral Bone. Changes in the osteochondral surface and subchondral bone are also a significant characteristic of TMJOA, whose clinical diagnosis can therefore be made on the basis of imaging findings [32]. While the remodeling process is always well-organized and maintains skeletal homeostasis under physiological conditions [33], imbalanced osteoblastic bone formation and osteoclast-mediated bone resorption can be observed in the osteoarthritic condyle. The loss of subchondral trabecular bone with decreased bone volume to tissue volume (BV/TV) and increased osteoclastic activity can be observed in experimental TMJOA animal models, such as unilateral anterior crossbite (UAC) rats, as confirmed in the literature [34–36]. A previous study reported that inhibited activity of local BMSCs decreased numbers of osteoblasts and osteoclasts at two weeks in UAC-treated cells [34]. However, it was observed that although the numbers of BMSCs and Ocn-positive osteoblasts declined, the osteogenic potential of BMSCs was stimulated, thereby strongly promoting the migration and differentiation of osteoclast precursors mediated by the Wnt5a/Ror2 signaling pathway, and finally resulting in an osteoclastic predominant, resorptive subchondral trabecular bone phenotype [37]. Moreover, researchers have also found that aberrant activation of transforming growth factor-β (TGF-β) in subchondral bone has participated in the initiation and progression of TMJOA [36, 38]. CED mice, an osteoblast-specific mutant TGF-β1 transgenic mouse model, displayed calcification degeneration of TMJ cartilage, loss of subchondral bone due to disrupted bone formation with high levels of active TGF-β, and inhibition of TGF-β receptors, which attenuated TMJOA development and restored bone mass.

Recently, studies indicated that sympathetic tone, which was shown to be associated with osteoarthritic pain [39], was also related to abnormal bone remodeling. It was found that β2-adrenergic signal transduction elicited subchondral bone loss and cartilage degradation by increasing RANKL secretion by MSCs in the condyle, while β-antagonist (propranolol) and conditional deletion of β2-adrenergic receptor
(Adrb2) in nestin+ MSCs suppressed bone defects in the TMJ [40, 41]. Additionally, inflammatory mediators and immune responses also accelerate bone resorption via osteoclast activation [23]. Besides loss of trabecular bone, the disrupted balance of bone remodeling also leads to thickening, calcification, and stiffening of the osteochondral interface, as well as deformation of the condyle [36, 42]. Since the osteochondral interface and osteocytes are extremely sensitive to mechanical overload [23], the change in subchondral bone may exacerbate OA progression, which requires further confirmation [42].

2.3. Apoptosis and Anomalies of Chondrocytes. A major feature of TMJOA, the destruction of cartilage, was reported to be mainly attributed to apoptosis or other chondrocyte anomalies [43]. Several studies have indicated that through the activation of endoplasmic reticulum stress (ERS), some widely known pathogenic factors of OA, such as mechanical forces and hypoxia, can induce chondrocyte apoptosis and OA-like changes in the temporomandibular joint, and inhibition of the endoplasmic reticulum can reduce apoptosis and alleviate destruction of mandibular cartilage [44, 45]. A recent study has further explored the underlying mechanism of ERS pathway apoptosis (ERS-apoptosis) in TMJOA [46]. Experimental TMJOA models activated ERS and induced both ERS-apoptosis and protective autophagy in chondrocytes in the early stage, but the switch from autophagy to apoptosis, mediated by MTORC1, led to cartilage loss and progression of biomechanically induced TMJOA [47, 48]. In addition to ERS-apoptosis, inflammation is involved in the pathogenesis of TMJOA; a recent study also found that inflammatory synoviocytes in TMJ could facilitate lipopolysaccharide- (LPS-) induced apoptosis of chondrocytes by increasing TNF-α, which is regulated by long noncoding RNA plasmacytoma variant translocation 1 (PVT1) [49, 50].

Moreover, abnormal terminal differentiation of chondrocytes also contributes to cartilage degeneration in TMJOA, while expression levels of Col-X, MMP13, and ALP, the markers that represent the hypertrophic stage, are often elevated in OA cartilage [51–53]. Studies have revealed that accelerated terminal differentiation in chondrocytes, which leads to cartilage degeneration, is one of the typical characteristics in TMJOA animal models, and the underlying molecular mechanism is related to Indian hedgehog (Ihh), parathyroid hormone receptor 1 (PTH1R), calcium-sensing receptor (CaSR), induced by aberrant biomechanical stress [54–56].

2.4. Hypoxia and Angiogenesis. Recent studies have also focused on the complicated role played by hypoxia and angiogenesis in the onset and development of TMJOA. While some studies pointed out that HIF1α may maintain cartilage homeostasis in a protective way, other researchers have indicated that the HIF1-VEGF-Notch pathway accelerates TMJOA progression [57, 58]. In experimental TMJOA rats, expression levels of HIF1α, VEGF, and Notch-1 in hypoxic chondrocytes were significantly higher, together with pathological angiogenesis at the osteochondral junction [58–60]. Inhibition of HIF1α or Notch pathways can partially delay the progression of OA [61].

Another hypoxia inducible factor, HIF2α, also participates in cartilage destruction via multiple mechanisms. As osteoarthritic changes can be triggered by an imbalance between catabolic and anabolic factors, HIF2α directly induces the upregulation of matrix metalloproteinases (MMPs), aggrecanase-1 (ADAMTS4), nitric oxide...
Mesenchymal stem cells (MSCs) are multipotent progenitor cells with the capability of self-renewal and differentiation into multiple lineages. As MSCs are highly heterogeneous populations, finding a single unambiguous phenotypic marker for MSCs is still an unsettled issue; therefore, identification is based on a panel of both positive and negative markers [15]. As recommended by the International Society of Cellular Therapy, MSCs should be identified as plastic-adherent cells, with expressions of CD73, CD90, and CD105 and the absence of hematopoietic markers and HLA class II molecules, and possess tripotent differentiation into chondrogenic, osteogenic, and adipogenic phenotypes [76, 77]. In the past few years, numerous preclinical and clinical studies have been conducted on the utility of MSCs in osteoarthritis of other joints, such as the knee meniscus, demonstrating the therapeutic effects of MSCs on cartilage regeneration, symptom alleviation, and pain management [10, 78–81]. The regenerative characteristics of MSCs and these optimistic results have catapulted them to the forefront of TMJOA cellular treatment in recent years.

3.1. Bone Marrow Mesenchymal Stem Cells (BMMSCs). Currently, bone marrow is the most common MSC source in clinical practice and has been widely studied in the field of cartilage repair, either alone or with scaffolds. Although there are limitations, such as donor site morbidity, bone marrow mesenchymal stem cells (BMMSCs) are superior in cell proliferation and chondrogenic differentiation ability [82]. Notably, immune escape is a significant feature of BMMSCs, which allows for clinical applications of xenogenic MSCs, without resulting in an obvious inflammatory reaction [83–85]. Several studies have indicated that an exogenous supply of BMMSCs exerts therapeutic effects on TMJOA via multiple mechanisms [48, 83, 86]. It has been reported that continual BMMSC injections rescued cartilage degradation and abnormal subchondral bone remodeling, leading to improved BV/TV, Tb. Sp, and cartilage thickness, together with decreased loss of glycosaminoglycans [83]. Researchers further determined that the reparative effect of BMMSCs on cartilage mainly relies on promoting cartilage matrix production and activating protective scavenging activity, resulting in a reduction in chondrocyte apoptosis in the replenished matrix [48]. Moreover, BMMSCs display immunomodulatory effects by secreting anti-inflammatory factors [87]. Upregulated levels of TNF-α and IL-1β in mice with osteoarthritic TMJ returned to control levels after the administration of BMMSC injections [83]. In addition, studies have suggested that the direct incorporation and differentiation of chondrocytes may also participate in the therapeutic process [88], and it was observed that chondrogenically differentiated MSCs were more effective in delaying the progression of TMJOA in vitro, especially during the early period [86].

Apart from injections, tissue engineering provides a final-stage solution for severe TMJOA; BMMSCs combined with tissue engineering techniques exhibited promising effects on TMJOA treatment. A previous study showed that a BMMSC-containing scaffold with a periosseal or synovial flap led to fibrocartilage tissue repair 12 months post-surgery [89]. Combined with a microprecise spatiotemporal delivery system for growth factors embedded in 3D printed TMJ scaffolds, bone marrow-derived and synovium-derived MSCs can be induced into regionally controlled differentiation, resulting in the formation of multiphase fibrocartilaginous tissues [90]. Similarly, it was observed that BMMSCs seeded in 3D-printed scaffolds with growth factors, such as transforming growth factor-β (TGF-β) and connective tissue growth factor (CTGF), resulted in a heterogeneous fibrocartilaginous matrix, further proving its potential for TMJ tissue engineering and TMJOA treatment [91].

3.2. Adipose Stem Cells (ASCs). Adipose tissue is also a highly attractive source of mesenchymal stem cells [92]. While the immunophenotypes of BMMSCs and ASCs are more than 90% identical, compared to BMMSCs, adipose-derived stem cells (ASCs) that present multilineage differentiation are easily obtainable, owing to the ubiquitous adipose tissue in the body and ease of extraction and isolation [93–95]. Besides, the strengths of ASCs also include their abundance in
adipose tissue, manipulability, rapid growing ability, and less interference by age than BM-MSCs [96–98]. Notably, ASCs are capable of replicating the extracellular matrix environment of implanting sites with different types of collagen and undergoing hypoxic conditions, which makes implantation possible in the lowly vascularized TMJ structure [99]. In recent years, ASCs have been shown to represent a promising therapeutic strategy for osteoarthritis [100]. Many clinical trials or case reports demonstrated that intra-articular injections of ASCs into patients with knee osteoarthritis led to safe and satisfactory results involving functional improvement, pain relief, and delayed progression of OA, without severe adverse effects reported yet [78, 101–103].

In 2010, an *in vitro* study showed that adipose stem cells cultured in chondrogenic conditions combined with polylactide (PLA) discs can be used in TMJ disc engineering, creating constructs that can replace degenerated TMJ discs [99]. The authors further conducted a similar *in vivo* study using ASCs cultured in PLA discs in TMJs of rabbits. These results proved that the use of ASCs, especially predifferentiated with TGF-β1 in TMJ engineering, promoted fibrocartilaginous TMJ disc-like tissue formation [104]. More recently, a study obtained positive outcomes after autologous ASC infiltration in the TMJ superior compartment of patients suffering from temporomandibular disorders [105]. They found that ASC injections with arthrocentesis led to the alleviation of symptoms and restoration of articular anatomical integrity, as demonstrated by MRI findings. However, since the study focused on TMJ internal derangement (ID) and is associated with a relatively high risk of bias, further investigations are required regarding the applications of ASCs for TMJ OA treatment.

3.3. Umbilical Cord Mesenchymal Stem Cells (UC-MSCs). Umbilical cord mesenchymal stem cells (UC-MSCs), which can be obtained from various umbilical cord compartments, such as Wharton’s jelly (WJ), perivascular tissue (PVT), and endovascular compartment (UCB), through a painless and safe procedure, are also a promising stem cell resource in regenerative medicine [106–108]. In addition, compared to other MSCs, UC-MSCs are relatively young cell type with great proliferation and differentiation capability, and have no ethical concerns or tumorigenesis possibility, unlike embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) [109–112].

Previous studies have proved that instead of generating hyaline cartilage, the strong potential for fibrocartilage production by UC-MSCs has turned them into a desirable option for TMJ tissue engineering [111, 113]. A study by Bailey et al. suggested that in comparison with TMJ condylar chondrocytes, UC-MSC-seeded PLA constructs displayed higher levels of biosynthesis and cellularity [114]. An *in vitro* study by Wang et al. using 3D scaffolds also revealed that UC-MSCs outperformed BM-MSCs in terms of fibrocartilage regeneration, with greater amounts of type I collagen and aggrecan produced [113]. They also found that a higher initial seeding density of UC-MSCs led to enhanced mechanical integrity and biosynthesis of newly synthesized fibrocartilage [115]. Recently, a study by Kim et al. demonstrated that intra-articular UC-MSC injections exert therapeutic potential in a rabbit model of TMJ OA [116]. With upregulated expression of growth factors, extracellular matrix markers, and anti-inflammatory cytokines, transplanted UC-MSCs not only ameliorated degeneration of cartilage and subchondral bones, but also exerted pronounced anti-inflammatory effects, analogous to dexamethasone (DEX). Additionally, the restorative effects can last for a minimum of four weeks, without local or general complications. Some osteoarthritic animal models also confirmed this curative effect by UC-MSCs, showing improved structures, suppressed inflammation, and relatively promoted clinical signs [117, 118].

3.4. Tooth-Derived Mesenchymal Stem Cells. A great variety of tooth-derived stem cells, including periodontal ligament stem cells (PDLSCs), dental pulp stem cells (DPSCs), dental follicle progenitor cells (DFPCs), and dental pulp stem cells from deciduous teeth (SHED), have been proposed as promising candidates in the field of regenerative medicine [119–121]. In addition to their proliferation and self-renewal capacities similar to BM-MSCs, tooth-derived stem cells, such as PDLSCs, SHEDs, and DPSCs, are also capable of differentiating into chondrocytes and osteoblasts, and therefore adequate for tissue repair outside of tooth structures [122–125]. Moreover, compared to BM-MSCs, tooth-derived stem cells may display a high affinity for regenerating craniofacial tissues, based on the same embryological origins they share and similar gene expression patterns [126, 127].

Although previous studies have focused on the potential of dental stem cells in articular cartilage repair [125, 128, 129], Bousnaki et al. first revealed applications of dental pulp stem cells (DPSCs) in TMJ tissue engineering [130]. DPSCs exhibited enhanced fibro-/chondrogenic differentiation and abundant fibrocartilaginous tissue formation when seeded into chitosan/alginate (Ch/Alg) scaffolds with an interconnected porous structure. Compared to cell-free scaffolds, constructs with DPSCs obtained markedly promoted storage modulus and elastic response, similar to natural TMJ discs. Notably, some studies revealed that instead of directly differentiating into chondrocytes, dental stem cells participated in the TMJ regeneration process via a paracrine mechanism [131, 132]. The trophic roles of MSCs have been extensively investigated [133–136]. A study by Zhang et al. demonstrated that periodontal ligament stem cells (PDLSCs) facilitate fibrocartilage regeneration in TMJ disorders by stimulating proliferation and extracellular matrix formation of TMJ-derived chondrocytes [131]. Similarly, it was found that factors secreted by stem cells from human exfoliated deciduous teeth (SHED), a kind of MSC residing in the periodontal ligament of deciduous teeth, can induce the differentiation of BM-MSCs into osteoblasts and chondrocytes [137]. Moreover, intravenous administration of SHED-derived conditioned media effectively stimulated cartilage and bone regeneration in TMJ OA [138].

3.5. Joint-Derived Mesenchymal Stem Cells. Besides the aforementioned tissues, the joint itself also harbors a rich mesenchymal stem cell reservoir, such as MSCs in synovial fluid.
thritic large joints have yielded encouraging outcomes of joint-derived MSCs on meniscal regeneration or osteoarthritis in vivo exhibited similar potential in TMJ disc regeneration. An in vivo study showed that TMJ-synovial stem cells underwent chondrogenic differentiation and produced cartilage ECM when seeded in fibrin/chitosan scaffolds, demonstrating a regenerative ability for perforated TMJ discs, often seen in the late stage of TMJOA.

Aside from applications with extracted and subsequently implanted MSCs, manipulation of joint-resident stem cells may also serve as a novel therapeutic target for TMJOA. It is generally acknowledged that joint-resident MSCs could be mobilized by multiple recruiting signals and exert reparative effects on destroyed cartilage through chondrogenic differentiation, ECM reconstruction, and immunomodulation. This could be partially confirmed by increasing amounts of MSCs in osteoarthritic synovium or synovial fluids. While joint irrigation with arthroscopy has been a classical method for osteoarthritis, the side effect of lavage-depleting joint-resident SF-MSCs, may lead to undesirable results that go against traditional experience. Accordingly, Baboolal et al. developed a novel arthroscopic technique aimed at mobilizing resident SF-MSCs to promote the endogenous repair potential of joints.

However, this reparative capacity of joint-resident MSCs could be inhibited by one of the key factors in the pathogenesis of TMJOA and inflammation. It was found that proinflammatory cytokines, such as IL-1β, impede the chondrogenic potential of SF-MSCs or SD-MSCs in osteoarthritic TMJ, and make these MSCs in osteoarthritic joints further secrete proinflammatory cytokines such as IL-6 or IL-8. Therefore, medications targeting inflammatory pathways in MSCs, such as histone deacetylation inhibitors LBH589, SAHA, and MC1568, may provide new insights into TMJOA treatment by attenuating MSC-secreted cytokines. Interestingly, Embree et al. identified a type of resident fibrocartilage stem cell (FCSC) in the superficial zone niche of the TMJ condyle. The depletion of these cells by overactive Wnt signals would disturb the homeostasis of TMJ fibrocartilage and result in its degeneration. Based on this newly proposed pathological mechanism, exploiting resident FCSCs with exogenous canonical Wnt inhibitor sclerostin (SOST) for condylar cartilage repair may present a novel cell-based therapy.

4. Other Cellular-Based Therapies for TMJOA

4.1. Exosomes. As previously discussed, an increasing amount of literature has indicated that, rather than direct chondrogenic differentiation, the therapeutic efficacy of MSCs is predominantly attributed to paracrine secretion, where exosomes play a major role. Exosomes are nanosized (30-150 nm) extracellular vesicles (EVs), released through the fusion of multivesicular bodies with the plasma membranes from various cell types. With their complex cargos and bilipid membrane structures, exosomes primarily function as intercellular communication vehicles, transferring bioactive lipids, nucleic acids (mRNAs and microRNAs), and proteins between cells under both physiological and pathological conditions.

To date, exosomes have been isolated from different types of stem cells, including ASCs, BM-MSCs, UC-MSCs, ESCs, and iPSCs. These stem cell-derived exosomes exert therapeutic effects against various diseases, such as myocardial ischemia/reperfusion injury and renal injury, and promote cartilage and bone regeneration. Exosomes have also catapulted to the forefront of TMJOA cellular therapies, although the research is relatively limited.

In 2019, a study by Zhang et al. first revealed the therapeutic role of human MSC exosomes in TMJOA. Through a well-orchestrated mechanism that targets several critical features of TMJOA pathology, MSC exosomes alleviate osteoarthritic TMJ deterioration and promote repair and regeneration. These protective effects of MSC exosomes can be partially attributed to adenosine receptor-dependent AKT, ERK, and AMPK signaling pathways. Additionally, the MSC exosomes also exhibited immunomodulatory activity during the osteochondral process, as they can elicit infiltration of regenerative and anti-inflammatory M2 macrophages over M1 macrophages, whose polarization in osteoarthritic tissue inhibits chondrogenic differentiation of MSCs. In addition, the complex cargos of MSC exosomes may serve as major curative agents for TMJOA. Luo et al. recently found that exosomes derived from human exfoliated deciduous teeth (SHEDs) exert anti-inflammatory effects in TMJOA, which rely on the exosomal cargo, miR-100. miR-100 in SHED-exosomes suppresses the expression of proinflammatory cytokines and catabolic enzymes, such as IL-6; IL-8; and MMP1, 3, 9, and 13, via repression of mammalian target of rapamycin (mTOR) pathways.

4.2. Minimally Manipulated MSC (BMAC and SVF). Although in recent years, MSC-based therapy has rapidly progressed in the field of OA and cartilage regeneration, with considerable optimistic outcomes from animal and human studies, the clinical applications of MSCs are still under strict restrictions by the Food and Drug Administration (FDA), particularly with regard to cell expansion. This regulatory limitation has incentivized clinicians to develop alternative cell-based methods with MSCs, the so-called minimally manipulated MSCs, which means that cells are directly manipulated near the operating room prior to implantation.
instead of expansion before. Bone marrow aspirate concentrate (BMAC) and adipose-derived stromal vascular fraction (SVF) are two major modalities of minimally manipulated MSCs.

Obtained through bone marrow needle aspirates and subsequent centrifugation [177], BMAC has complex cellular elements, including BMMSCs and other components such as bone marrow-derived platelets [176]. While many researchers have reported positive results using BMAC in knee osteoarthritis patients, such as improvement in pain and function [178–180], a randomized controlled trial with 12-month follow-up by Shapiro et al. indicated that no significant differences existed between BMAC- and saline-treated patients [181, 182]. Moreover, as no clinical trials involving BMACs have been conducted, there is also a vacancy in BMAC application in osteoarthritic TMJ or fibrocartilage regeneration, requiring further studies in this regard. Conversely, clinical applications of SVF have produced more stable and satisfactory outcomes in OA or cartilage regeneration, relative to BMAC. SVF, a potent regenerative solution containing ASCs, is a component of liposapirate, the collection of which involves multiple steps, such as liposuction, digestion of the extracellular matrix (ECM), and centrifugation [84]. An alternative SVF isolation method is nano­fragmented adipose tissue (nanofat), with retained ECM to maintain the intact microenvironment of stem cells [183].

Several studies have indicated positive clinical outcomes of SVF administration in knee OA cases, with improvements in articular function, clinical symptoms, MRI results, and even histological findings from knee biopsies [184–187]. However, a recent systematic review pointed out that a lack of high-quality and well-designed clinical studies weakened the credibility of encouraging results after BMAC or SVF applications [176]. Additionally, the limited number of research participants and concomitant use of other curative agents, such as dexamethasone, hyaluronic acid (HA), and platelet-rich plasma (PRP), also undermined the distinct identification of their effects [84]. More recently, studies have also started to focus on the potential effect of SVF on TMD disorders. A study evaluated the efficacy of intra-articular nanofat injection for patients with TMD and found a remarkable improvement in all four parameters (pain level, maximum mouth opening (MMO), joint clicking, and deviation), without significant side effects or complications [188]. In addition, another in vitro study published in 2020 reported that SVF, which contained 32% ASCs via their modified isolation method, downregulated the expression of OA-related inflammatory cytokines, such as PGE2 and CXCL8/IL-8, in osteoarthritic TMJ synoviocytes [189]. The PGE2 decrease was more prominent in SVF than in ASCs, suggesting that other components of SVF participated in the anti-inflammatory effect. Overall, although further in vivo and preclinical studies are needed, these studies revealed that SVF may be a feasible cellular therapy for TMJOA in the future.

5. Limitations of Cell-Based Therapies for TMJOA

In recent years, despite increasing studies that have shed light on the potential capability of cell-based therapies for TMJOA, unfortunately, many problems still impede its application in clinical settings. One of the major obstacles in MSC application is the absence of a specific and clear understanding of the therapeutic mechanisms, due to the complexity of MSC metabolism and difficulty of cell fate mapping. As previous studies primarily anchored their hope on the multilineage differentiation ability of MSCs [86], some researchers have pointed out that the retention rate of transplanted MSCs in the OA joint was relatively low, suggesting that the therapeutic role relies more on alternative mechanisms, such as a paracrine effect [15].

Another major problem is that the hostile environment of osteoarthritic joints may undermine the functions of MSCs, either joint-resident or transplanted, such as their viability, chondrogenic ability, and immunomodulatory effects [141, 142]. Increasing evidence suggests that MSCs may upregulate inflammation under certain OA conditions, and may even differentiate into a proinflammatory phenotype or become a new source of inflammatory cytokines, as discussed [153, 190, 191]. Some studies have attempted to solve this problem by optimizing MSCs with signaling pathway inhibition, such as STAT3, which yields satisfactory outcomes [192]. However, further research regarding the underlying mechanism is still required. Many basic questions about cellular therapies are still calling for definite answers, such as the optimal cell source, cell dose, injection times, or intervals. Additionally, the lack of a consistent approach in trial designs presents a hurdle to the adoption of these treatments. As MSC exosomes represent a more accessible, “off-the-shelf,” and cell-free MSC therapy, significant challenges and considerations in terms of manufacture, safety, long-term durability, and regulation still remain, which should be thoroughly discussed before its translation to clinical trials [193].

6. Conclusions

Due to the complicated pathogenesis of TMJOA and poor self-healing capability of a condylar structure, current management for this degenerative disease, both conservative and surgical, are mainly symptomatic therapies. Unmet clinical needs for effective, long-term, disease-modifying strategies to regenerate the osteoarthritic TMJ structure still exist, and therefore lead to the increasing interest in cellular-based therapies, namely mesenchymal stem cells (MSCs) and their related derivatives, such as exosomes and minimally manipulated MSCs. Applications of exogenous MSCs from abundant sources alone or in conjunction with tissue engineering have exhibited promising results preclinical studies involving TMJOA, revealing rescued cartilage degradation, pronounced fibrocartilaginous tissue or matrix formation, and decreased inflammatory levels (Table 1). Although the reparative effects were mainly ascribed to chondrogenic differentiation of MSCs, current studies tend to emphasize the paracrine mechanisms of MSCs. Furthermore, interventions that harnessed endogenous joint-derived MSCs or exosomes also exhibited remarkable potential for TMJOA treatments.

Although many hurdles regarding the principles and specific usages of MSCs still remain, and nearly all the aforementioned studies rest on the preclinical stage, current evidence
| Cell                                           | Interventions                                                                 | Operative ways                                                                 | Animal          | Dosage                                                                 | Cartilage | Subchondral bone | Inflammation | Refs.          |
|------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|----------------|------------------------------------------------------------------------|-----------|-----------------|--------------|----------------|-------------|
| Bone marrow mesenchymal stem cells (BMSCs)     | Local injections of $2 \times 10^3$ exogenous BMSCs                           | Mouse                                                                         | Weekly, 3 weeks after OA induction; continuing for 4-, 8- and 12-weeks. | Yes | Yes | Yes | [48, 83] |
|                                                | Local injection of $2 \times 10^5$ autologous BMSC                            | Rabbit                                                                        | One time, 4 weeks after OA induction                                     | Yes | Yes | N/A | [86] |
|                                                | $2 \times 10^6$ cells/ml BMSCs with 3D-printed scaffolds                      | Rabbit                                                                        | One time, cultured for 6 weeks with 1:1 mixture of fibrogenic and chondrogenic supplements | Yes | N/A | N/A | [90, 91] |
| Adipose stem cells (ASCs)                      | $1 \times 10^5$ ASCs with TMJ disc-shaped bilayer biodegradable PLA disc     | In vitro                                                                      | Cultured for a maximum of 6 weeks                                       | Yes | N/A | N/A | [99, 104] |
|                                                | $4 \times 10^4$ ASCs with bilayer PLA discs                                  | Rabbit                                                                        | One time, follow-up periods of 6 ($n = 5$) and 12 months ($n = 5$)       | Yes | Yes | N/A | [104] |
|                                                | Local injections of 1 cc autologous ASCs by arthrocentesis                   | Human                                                                          | One time, 6 month follow-up                                              | Yes | Yes | Yes | [105] |
| Umbilical cord Mesenchymal stem cells (UC-MSCs)| $3.4 \times 10^6$ UC-MSCs with PGA scaffolds                                  | In vitro                                                                      | Seeded in the scaffolds for 6 days and cultured for 4 weeks              | Yes | N/A | N/A | [114] |
|                                                | Intra-articular injections of $2 \times 10^4$ ~ $2 \times 10^5$ UC-MSCs       | Rabbit                                                                        | One time, injections at 4 weeks after OA induction; sacrificed at 8 weeks after OA induction | Yes | Yes | Yes | [116] |
| Tooth-derived mesenchymal stem cells (including PDLSCs, DPSCs, DFPCs, and SHEDs) | $2 \times 10^6$ DPSCs seeded in chitosan/alginate scaffolds with an interconnected porous structure | In vitro                                                                      | DPSCs were cultured for 21 days before seeding; the DPSCs/scaffold constructs were incubated for up to 8 weeks | Yes | N/A | N/A | [130] |
|                                                | $1 \times 10^5$ PDLSCs                                                       | In vitro                                                                      | Cocultured with $1 \times 10^5$ fibrochondrocytes for 3 weeks           | Yes | N/A | N/A | [131] |
|                                                | Tail vein injection of conditioned media from SHED                          | Rat                                                                            | Daily, from day 6 to day 10                                             | Yes | Yes | Yes | [132] |
| Joint-derived mesenchymal stem cells           | $2 \times 10^6$ MSCs from the TMJ-synovial membrane with fibrin/chitosan scaffolds | Rat                                                                            | One time, 4 weeks of subcutaneous implantation                           | Yes | N/A | N/A | [149] |
|                                                | Intra-articular treatment with the Wnt inhibitor sclerostin (SOST)           | Rabbit                                                                        | Weekly, from week 1 to week 7                                          | Yes | N/A | N/A | [140] |
| Exosomes                                       | Intra-articular injections of 100 μg exosomes                                | Rat                                                                            | Weekly, 2 weeks after OA induction, continuing for 2, 4, or 8 weeks    | Yes | Yes | Yes | [13] |
for these cellular-based therapies reveals the feasibility of revolutionizing traditional therapeutic options for TMJ OA. However, further in vivo studies are required to overcome existing problems, in order to move these methods from bench to bedside, both efficiently and safely.

Data Availability
No data were used to support this study.

Conflicts of Interest
The authors declare that there are no conflicting interests regarding the publication of this paper.

Authors’ Contributions
Y. Z. was the chief performer of the study and was engaged in data analyses and interpretation. Y. Z. and L.X. were involved in study conception and design. The manuscript was written and revised by Y. Z. and L.X.

Acknowledgments
This work was supported by grants from the National Natural Science Foundation of China (NSFC, 82071137), CAMS Innovation Fund for Medical Science (CIFMS, 2019-12M-5-004), and the Sichuan Province Science and Technology Support Program (2020YJ0286 and 2019YFS0357).

References


[54] H. Yang, M. Zhang, Q. Liu et al., “Inhibition of Ihh reverses temporomandibular joint osteoarthritis via a PTH1R


[84] S. Lopa, A. Colombini, M. Moretti, and L. de Girolamo, “Injective mesenchymal stem cell-based treatments for knee osteoarthritis: from mechanisms of action to current clinical


[95] L. Mazini, L. Rochette, M. Amine, and G. MalkaRegenerative capacity of adipose derived stem cells (ADSCs), comparison with mesenchymal stem cells (MSCs),” *International Journal of Molecular Sciences*, vol. 20, article 2523, no. 10, 2019.


